Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study.
Doubek M, Brychtova Y, Panovska A, Sebejova L, Stehlikova O, Chovancova J, Malcikova J, Smardova J, Plevova K, Volfova P, Trbusek M, Mraz M, Bakesova D, Trizuljak J, Hadrabova M, Obrtlikova P, Karban J, Smolej L, Oltova A, Jelinkova E, Pospisilova S, Mayer J. Doubek M, et al. Among authors: stehlikova o. Am J Hematol. 2015 May;90(5):417-21. doi: 10.1002/ajh.23964. Epub 2015 Apr 1. Am J Hematol. 2015. PMID: 25645263 Free article. Clinical Trial.
Fludarabine with cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with poor-risk chronic lymphocytic leukemia.
Krejci M, Doubek M, Brychtova Y, Stehlikova O, Chovancova J, Tichy B, Francova HS, Navratil M, Tomiska M, Horky O, Pospisilova S, Mayer J. Krejci M, et al. Among authors: stehlikova o. Ann Hematol. 2013 Jan;92(2):249-54. doi: 10.1007/s00277-012-1579-y. Epub 2012 Sep 27. Ann Hematol. 2013. PMID: 23014659 Clinical Trial.
Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice.
Stehlíková O, Chovancová J, Tichý B, Krejčí M, Brychtová Y, Panovská A, Francová Skuhrová H, Burčková K, Borský M, Loja T, Mayer J, Pospíšilová S, Doubek M. Stehlíková O, et al. Int J Lab Hematol. 2014 Apr;36(2):165-71. doi: 10.1111/ijlh.12149. Epub 2013 Sep 13. Int J Lab Hematol. 2014. PMID: 24028768
Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia.
Janovska P, Poppova L, Plevova K, Plesingerova H, Behal M, Kaucka M, Ovesna P, Hlozkova M, Borsky M, Stehlikova O, Brychtova Y, Doubek M, Machalova M, Baskar S, Kozubik A, Pospisilova S, Pavlova S, Bryja V. Janovska P, et al. Among authors: stehlikova o. Clin Cancer Res. 2016 Jan 15;22(2):459-69. doi: 10.1158/1078-0432.CCR-15-0154. Epub 2015 Aug 3. Clin Cancer Res. 2016. PMID: 26240275 Free PMC article.
ROR1-based immunomagnetic protocol allows efficient separation of CLL and healthy B cells.
Kotašková J, Pavlová Š, Greif I, Stehlíková O, Plevová K, Janovská P, Brychtová Y, Doubek M, Pospíšilová Š, Bryja V. Kotašková J, et al. Among authors: stehlikova o. Br J Haematol. 2016 Oct;175(2):339-342. doi: 10.1111/bjh.13848. Epub 2015 Nov 16. Br J Haematol. 2016. PMID: 26567475 Free article. No abstract available.
Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.
Greil R, Obrtlíková P, Smolej L, Kozák T, Steurer M, Andel J, Burgstaller S, Mikušková E, Gercheva L, Nösslinger T, Papajík T, Ladická M, Girschikofsky M, Hrubiško M, Jäger U, Fridrik M, Pecherstorfer M, Králiková E, Burcoveanu C, Spasov E, Petzer A, Mihaylov G, Raynov J, Oexle H, Zabernigg A, Flochová E, Palášthy S, Stehlíková O, Doubek M, Altenhofer P, Pleyer L, Melchardt T, Klingler A, Mayer J, Egle A. Greil R, et al. Among authors: stehlikova o. Lancet Haematol. 2016 Jul;3(7):e317-29. doi: 10.1016/S2352-3026(16)30045-X. Epub 2016 Jun 16. Lancet Haematol. 2016. PMID: 27374465 Clinical Trial.
Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial.
Egle A, Melchardt T, Obrtlíková P, Smolej L, Kozák T, Steurer M, Andel J, Burgstaller S, Mikušková E, Gercheva L, Nösslinger T, Papajík T, Ladická M, Girschikofsky M, Hrubiško M, Jäger U, Voskova D, Pecherstorfer M, Králiková E, Burcoveanu C, Spasov E, Petzer A, Mihaylov G, Raynov J, Oexle H, Zabernigg A, Flochová E, Palášthy S, Stehlíková O, Doubek M, Altenhofer P, Weiss L, Magnes T, Pleyer L, Klingler A, Mayer J, Greil R. Egle A, et al. Among authors: stehlikova o. Cancer Med. 2019 Apr;8(4):1401-1405. doi: 10.1002/cam4.1980. Epub 2019 Mar 19. Cancer Med. 2019. PMID: 30888118 Free PMC article. Clinical Trial.
24 results